Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options

International Journal of Medical Microbiology

Volumn 306, Issue 1, 2016, Pages 48-58

  Chatterjee, Maitrayee ^a   Anju, C P ^a   Biswas, Lalitha ^a   Anil Kumar, V ^a   Gopi Mohan, C ^a   Biswas, Raja ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti microbial peptides; Bacteriophages; Nanoparticles; Probiotic organisms; Pseudomonas aeruginosa; Quorum sensing

Indexed keywords

ANTIBIOTIC AGENT; IRON CHELATING AGENT; LACTOFERRIN; LECTIN; NANOPARTICLE; PLANT MEDICINAL PRODUCT; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; VACCINE; VIRULENCE FACTOR; BIOLOGICAL PRODUCT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; SHORT SURVEY; BIOLOGICAL THERAPY; DRUG EFFECTS; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS;

BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84983178030     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2015.11.004     Document Type: Short Survey

References (149)

1. Abdelghany S.M., Quinn D.J., Ingram R.J., Gilmore B.F., Donnelly R.F., Taggart C.C., Scott C.J. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int. J. Nanomedicine 2012, 7:4053-4063.
2. Abedon S.T., Kuhl S.J., Blasdel B.G., Kutter E.M. Phage treatment of human infections. Bacteriophage 2011, 1:66-85.
3. Ahmadi H., Tabaraie B., Maleknia S., Pormirzagholi F., Nejati M., Hedayati M.H. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine. J. Infect. Dev. Ctries 2012, 6:721-726.
4. Alexandre Y., Le Berre R., Barbier G., Le Blay G. Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections. BMC Microbiol. 2014, 14:107.
5. Azeredo J., Sutherland I.W. The use of phages for the removal of infectious biofilms. Curr. Pharm. Biotechnol. 2008, 9:261-266.
6. Banin E., Vasil M.L., Greenberg E.P. Iron and Pseudomonas aeruginosa biofilm formation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11076-11081.
7. Banin E., Lozinski A., Brady K.M., Berenshtein E., Butterfield P.W., Moshe M., Chevion M., Greenberg E.P., Banin E. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16761-16766.
8. Baumann U., Gocke K., Gewecke B., Freihorst J., von Specht B.U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir. Res. 2007, 8:57.
9. Bonev B., Hooper J., Parisot J. Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. J. Antimicrob. Chemother. 2008, 61:1295-1301.
10. Bumann D., Behre C., Behre K., Herz S., Gewecke B., Gessner J.E., von Specht B.U., Baumann U. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2007, 28:707-713.
11. Campodonico V.L., Llosa N.J., Grout M., Doring G., Maira-Litran T., Pier G.B. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect. Immun. 2010, 78:746-755.
12. Carpenter A.W., Worley B.V., Slomberg D.L., Schoenfisch M.H. Dual action antimicrobials: nitric oxide release from quaternary ammonium-functionalized silica nanoparticles. Biomacromolecules 2012, 13:3334-3342.
13. Chemani C., Imberty A., de Bentzmann S., Pierre M., Wimmerova M., Guery B.P., Faure K. Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands. Infect. Immun. 2009, 77:2065-2075.
14. Chen J., Han C.M., Lin X.W., Tang Z.J., Su S.J. Effect of silver nanoparticle dressing on second degree burn wound. Zhonghua Wai Ke Za Zhi 2006, 44:50-52.
15. Cornelis P., Dingemans J. Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections. Front. Cell. Infect. Microbiol. 2013, 3:75.
16. Cowell B.A., Evans D.J., Fleiszig S.M. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion. FEMS Microbiol. Lett. 2005, 250:71-76.
17. Cryz S.J., Lang A.B., Sadoff J.C., Germanier R., Furer E. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates. Infect. Immun. 1987, 55:1547-1551.
18. Cryz S.J., Sadoff J.C., Furer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb. Pathog. 1989, 6:75-80.
19. Cryz S.J., Lang A., Rudeberg A., Wedgwood J., Que J.U., Furer E., Schaad U. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst. Mitt. 1997, 345-349.
20. De D., Mandal S.M., Gauri S.S., Bhattacharya R., Ram S., Roy S.K. Antibacterial effect of lanthanum calcium manganate nanoparticles against Pseudomonas aeruginosa ATCC 27853. J. Biomed. Nanotechnol. 2010, 6:138-144.
21. Debarbieux L., Leduc D., Maura D., Morello E., Criscuolo A., Grossi O., Balloy V., Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 2010, 201:1096-1104.
22. Deguise I., Lagnouxa D., René R. Synthesis of glycodendrimers containing both fucoside and galactoside residues and their binding properties to Pa-IL and PA-IIL lectins from Pseudomonas aeruginosa. New J. Chem. 2007, 31:1321-1331.
23. DeLeon K., Balldin F., Watters C., Hamood A., Griswold J., Sreedharan S., Rumbaugh K.P. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob. Agents Chemother. 2009, 53:1331-1337.
24. Deng Y., Boon C., Chen S., Lim A., Zhang L.H. Cis-2-dodecenoic acid signal modulates virulence of Pseudomonas aeruginosa through interference with quorum sensing systems and T3SS. BMC Microbiol. 2013, 13:231.
25. Denton M., Kerr K., Mooney L., Keer V., Rajgopal A., Brownlee K., Arundel P., Conway S. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr. Pulmonol. 2002, 34:257-261.
26. Deslouches B., Islam K., Craigo J.K., Paranjape S.M., Montelaro R.C., Mietzner T.A. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother. 2005, 49:3208-3216.
27. Deziel E., Lepine F., Milot S., He J., Mindrinos M.N., Tompkins R.G., Rahme L.G. Analysis of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines (HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell communication. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1339-1344.
28. Diggle S.P., Matthijs S., Wright V.J., Fletcher M.P., Chhabra S.R., Lamont I.L., Kong X., Hider R.C., Cornelis P., Camara M., Williams P. The Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. Chem. Biol. 2007, 14:87-96.
29. Doring G., Meisner C., Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11020-11025.
30. Dubois V., Arpin C., Melon M., Melon B., Andre C., Frigo C., Quentin C. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J. Clin. Microbiol. 2001, 39:2072-2078.
31. Engel L.S., Hill J.M., Caballero A.R., Green L.C., O'Callaghan R.J. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa. J. Biol. Chem. 1998, 273:16792-16797.
32. Forestier C., Guelon D., Cluytens V., Gillart T., Sirot J., De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit. Care 2008, 12:R69.
33. Fu W., Forster T., Mayer O., Curtin J.J., Lehman S.M., Donlan R.M. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 2010, 54:397-404.
34. Galle M., Jin S., Bogaert P., Haegman M., Vandenabeele P., Beyaert R. The Pseudomonas aeruginosa type III secretion system has an exotoxin S/T/Y independent pathogenic role during acute lung infection. PLoS ONE 2012, 7:e41547.
35. Garbe J., Wesche A., Bunk B., Kazmierczak M., Selezska K., Rohde C., Sikorski J., Rohde M., Jahn D., Schobert M. Characterization of JG024, a pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol. 2010, 10:301.
36. Garcia-Contreras R., Perez-Eretza B., Lira-Silva E., Jasso-Chavez R., Coria-Jimenez R., Rangel-Vega A., Maeda T., Wood T.K. Gallium induces the production of virulence factors in Pseudomonas aeruginosa. Pathog. Dis. 2014, 70:95-98.
37. Geiszt M., Witta J., Baffi J., Lekstrom K., Leto T.L. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. FASEB J. 2003, 17:1502-1504.
38. Giacometti A., Cirioni O., Barchiesi F., Fortuna M., Scalise G. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1999, 44:641-645.
39. Gill E.E., Franco O.L., Hancock R.E. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem. Biol. Drug Des. 2014, 85:56-78.
40. Gocke K., Baumann U., Hagemann H., Gabelsberger J., Hahn H., Freihorst J., von Specht B.U. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol. Med. Microbiol. 2003, 37:167-171.
41. Gonzalez J.E., Keshavan N.D. Messing with bacterial quorum sensing. Microbiol. Mol. Biol. Rev. 2006, 70:859-875.
42. Grande K.K., Gustin J.K., Kessler E., Ohman D.E. Identification of critical residues in the propeptide of LasA protease of Pseudomonas aeruginosa involved in the formation of a stable mature protease. J. Bacteriol. 2007, 189:3960-3968.
43. Grimwood K., Kyd J.M., Owen S.J., Massa H.M., Cripps A.W. Vaccination against respiratory Pseudomonas aeruginosa infection. Hum. Vaccin. Immunother. 2015, 11:14-20.
44. Guilhelmelli F., Vilela N., Albuquerque P., Derengowski Lda S., Silva-Pereira I., Kyaw C.M. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front. Microbiol. 2013, 4:353.
45. Hagens S., Habel A., von Ahsen U., von Gabain A., Blasi U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 2004, 48:3817-3822.
46. Hagens S., Habel A., Blasi U. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microb. Drug Resist. 2006, 12:164-168.
47. Halwani M., Yebio B., Suntres Z.E., Alipour M., Azghani A.O., Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2008, 62:1291-1297.
48. Hauber H.P., Schulz M., Pforte A., Mack D., Zabel P., Schumacher U. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int. J. Med. Sci. 2008, 5:371-376.
49. Hauser A.R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol. 2009, 7:654-665.
50. Heeb S., Fletcher M.P., Chhabra S.R., Diggle S.P., Williams P., Camara M. Quinolones: from antibiotics to autoinducers. FEMS Microbiol. Rev. 2011, 35:247-274.
51. Hentzer M., Riedel K., Rasmussen T.B., Heydorn A., Andersen J.B., Parsek M.R., Rice S.A., Eberl L., Molin S., Hoiby N., Kjelleberg S., Givskov M. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002, 148:87-102.
52. Heo Y.J., Lee Y.R., Jung H.H., Lee J., Ko G., Cho Y.H. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 2009, 53:2469-2474.
53. Hertle R., Mrsny R., Fitzgerald D.J. Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein. Infect. Immun. 2001, 69:6962-6969.
54. Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2003, 9:32.
55. Holder I.A., Neely A.N., Frank D.W. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect. Immun. 2001, 69:5908-5910.
56. Hraiech S., Bregeon F., Rolain J.M. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des. Devel. Ther. 2015, 9:3653-3663.
57. Hurley M.N., Camara M., Smyth A.R. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J. 2012, 40:1014-1023.
58. Imperi F., Leoni L., Visca P. Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Front. Microbiol. 2014, 5:178.
59. Jakobsen T.H., Bragason S.K., Phipps R.K., Christensen L.D., van Gennip M., Alhede M., Skindersoe M., Larsen T.O., Hoiby N., Bjarnsholt T., Givskov M. Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 2012, 78:2410-2421.
60. Jarosz L.M., Ovchinnikova E.S., Meijler M.M., Krom B.P. Microbial spy games and host response: roles of a Pseudomonas aeruginosa small molecule in communication with other species. PLoS Pathog. 2011, 7:e1002312.
61. Jayaraman P., Sakharkar M.K., Lim C.S., Tang T.H., Sakharkar K.R. Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int. J. Biol. Sci. 2010, 6:556-568.
62. Jia J., Wang Y., Zhou L., Jin S. Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells. Infect. Immun. 2006, 74:6557-6570.
63. Jiang M., Yao J., Feng G. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa infection. PLOS ONE 2014, 9:e96609.
64. Jimenez P.N., Koch G., Thompson J.A., Xavier K.B., Cool R.H., Quax W.J. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol. Mol. Biol. Rev. 2012, 76:46-65.
65. Johansen H.K., Moskowitz S.M., Ciofu O., Pressler T., Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 2008, 7:391-397.
66. Johansson E.M., Crusz S.A., Kolomiets E., Buts L., Kadam R.U., Cacciarini M., Bartels K.M., Diggle S.P., Camara M., Williams P., Loris R., Nativi C., Rosenau F., Jaeger K.E., Darbre T., Reymond J.L. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem. Biol. 2008, 15:1249-1257.
67. Jyot J., Balloy V., Jouvion G., Verma A., Touqui L., Huerre M., Chignard M., Ramphal R. Type II secretion system of Pseudomonas aeruginosa: in vivo evidence of a significant role in death due to lung infection. J. Infect. Dis. 2011, 203:1369-1377.
68. Kandasamy S., Khan W., Evans F., Critchley A.T., Prithiviraj B. Tasco(R): a product of Ascophyllum nodosum enhances immune response of Caenorhabditis elegans against Pseudomonas aeruginosa infection. Mar. Drugs 2012, 10:84-105.
69. Kaneko Y., Thoendel M., Olakanmi O., Britigan B.E., Singh P.K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 2007, 117:877-888.
70. Kapoor R., Wadman M.W., Dohm M.T., Czyzewski A.M., Spormann A.M., Barron A.E. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2011, 55:3054-3057.
71. Kessler E., Safrin M., Abrams W.R., Rosenbloom J., Ohman D.E. Inhibitors and specificity of Pseudomonas aeruginosa LasA. J. Biol. Chem. 1997, 272:9884-9889.
72. Kohler T., Perron G.G., Buckling A., van Delden C. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 2010, 6:e1000883.
73. Kolomiets E., Swiderska M.A., Kadam R.U., Johansson E.M., Jaeger K.E., Darbre T., Reymond J.L. Glycopeptide dendrimers with high affinity for the fucose-binding lectin LecB from Pseudomonas aeruginosa. Chem. Med. Chem. 2009, 4:562-569.
74. Krishnan T., Yin W.F., Chan K.G. Inhibition of quorum sensing-controlled virulence factor production in Pseudomonas aeruginosa PAO1 by Ayurveda spice clove (Syzygium aromaticum) bud extract. Sensors (Basel) 2012, 12:4016-4030.
75. Kwan J.C., Meickle T., Ladwa D., Teplitski M., Paul V., Luesch H. Lyngbyoic acid, a "tagged" fatty acid from a marine cyanobacterium, disrupts quorum sensing in Pseudomonas aeruginosa. Mol. Biosyst. 2013, 7:1205-1216.
76. Lamb A.L. Breaking a pathogen's iron will: inhibiting siderophore production as an antimicrobial strategy. Biochim. Biophys. Acta 2015, 1854:1054-1070.
77. Lamers R.P., Cavallari J.F., Burrows L.L. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS ONE 2013, 8:e60666.
78. Lang A.B., Schaad U.B., Rudeberg A., Wedgwood J., Que J.U., Furer E., Cryz S.J. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J. Pediatr. 1995, 127:711-717.
79. Lee J.H., Kim Y.G., Cho M.H., Lee J. ZnO nanoparticles inhibit Pseudomonas aeruginosa biofilm formation and virulence factor production. Microbiol. Res. 2014, 169:888-896.
80. Leid J.G., Willson C.J., Shirtliff M.E., Hassett D.J., Parsek M.R., Jeffers A.K. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-γ-mediated macrophage killing. J. Immunol. 2005, 175:7512-7518.
81. Li X.Z., Barre N., Poole K. Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000, 46:885-893.
82. Lister P.D., Wolter D.J., Hanson N.D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 2009, 22:582-610.
83. Liu Y., Yang L., Molin S. Synergistic activities of an efflux pump inhibitor and iron chelators against Pseudomonas aeruginosa growth and biofilm formation. Antimicrob. Agents Chemother. 2010, 54:3960-3963.
84. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin. Infect. Dis. 2002, 34:634-640.
85. Loo C.Y., Young P.M., Lee W.H., Cavaliere R., Whitchurch C.B., Rohanizadeh R. Non-cytotoxic silver nanoparticle-polyvinyl alcohol hydrogels with anti-biofilm activity: designed as coatings for endotracheal tube materials. Biofouling 2014, 30:773-788.
86. Lorentzen D., Durairaj L., Pezzulo A.A., Nakano Y., Launspach J., Stoltz D.A., Zamba G., McCray P.B., Zabner J., Welsh M.J., Nauseef W.M., Banfi B. Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions. Free Radic. Biol. Med. 2011, 50:1144-1150.
87. Lusiak-Szelachowska M., Zaczek M., Weber-Dabrowska B., Miedzybrodzki R., Klak M., Fortuna W., Letkiewicz S., Rogoz P., Szufnarowski K., Jonczyk-Matysiak E., Owczarek B., Gorski A. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 2014, 27:295-304.
88. Manefield M., de Nys R., Kumar N., Read R., Givskov M., Steinberg P., Kjelleberg S. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology 1999, 145(Pt 2):283-291.
89. Manefield M., Rasmussen T.B., Henzter M., Andersen J.B., Steinberg P., Kjelleberg S., Givskov M. Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology 2002, 148:1119-1127.
90. Mansouri E., Gabelsberger J., Knapp B., Hundt E., Lenz U., Hungerer K.D., Gilleland H.E., Staczek J., Domdey H., von Specht B.U. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 1999, 67:1461-1470.
91. Mansouri E., Blome-Eberwein S., Gabelsberger J., Germann G., von Specht B.U. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol. Med. Microbiol. 2003, 37:161-166.
92. McGrath S., Wade D.S., Pesci E.C. Dueling quorum sensing systems in Pseudomonas aeruginosa control the production of the Pseudomonas quinolone signal (PQS). FEMS Microbiol. Lett. 2004, 230:27-34.
93. Mishra M., Byrd M.S., Sergeant S., Azad A.K., Parsek M.R., McPhail L., Schlesinger L.S., Wozniak D.J. Pseudomonas aeruginosa Psl polysaccharide reduces neutrophil phagocytosis and the oxidative response by limiting complement-mediated opsonization. Cell. Microbiol. 2012, 14:95-106.
94. Miyairi S., Tateda K., Fuse E.T., Ueda C., Saito H., Takabatake T., Ishii Y., Horikawa M., Ishiguro M., Standiford T.J., Yamaguchi K. Immunization with 3-oxododecanoyl-l-homoserine lactone-protein conjugate protects mice from lethal Pseudomonas aeruginosa lung infection. J. Med. Microbiol. 2006, 55:1381-1387.
95. Mohamed R.R., Sabaa M.W. Synthesis and characterization of antimicrobial crosslinked carboxymethyl chitosan nanoparticles loaded with silver. Int. J. Biol. Macromol. 2014, 69:95-99.
96. Mohan S., Oluwafemi O.S., George S.C., Jayachandran V.P., Lewu F.B., Songca S.P., Kalarikkal N., Thomas S. Completely green synthesis of dextrose reduced silver nanoparticles, its antimicrobial and sensing properties. Carbohydr. Polym. 2014, 106:469-474.
97. Moreau-Marquis S., O'Toole G.A., Stanton B.A. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am. J. Respir. Cell Mol. Biol. 2009, 41:305-313.
98. Moreau-Marquis S., Coutermarsh B., Stanton B.A. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J. Antimicrob. Chemother. 2015, 70:160-166.
99. Morita Y., Tomida J., Kawamura Y. Efflux-mediated fluoroquinolone resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7: identification of a novel MexS variant involved in upregulation of the mexEF-oprN multidrug efflux operon. Front. Microbiol. 2015, 6:8.
100. Moriyama K., Wiener-Kronish J.P., Sawa T. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Microbiol. Immunol. 2009, 53:587-594.
101. Naqvi S.Z., Kiran U., Ali M.I., Jamal A., Hameed A., Ahmed S., Ali N. Combined efficacy of biologically synthesized silver nanoparticles and different antibiotics against multidrug-resistant bacteria. Int. J. Nanomedicine 2013, 8:3187-3195.
102. Nguyen D., Emond M.J., Mayer-Hamblett N., Saiman L., Marshall B.C., Burns J.L. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr. Pulmonol. 2007, 42:533-541.
103. O'Loughlin C.T., Miller L.C., Siryaporn A., Drescher K., Semmelhack M.F., Bassler B.L. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:17981-17986.
104. Patel I.R., Rao K.K. Studies on the Pseudomonas aeruginosa PAO1 bacteriophage receptors. Arch. Microbiol. 1983, 135:155-157.
105. Pearson J.P., Feldman M., Iglewski B.H., Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect. Immun. 2000, 68:4331-4334.
106. Pennington J.E. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J. Infect. Dis. 1979, 140:73-80.
107. Poole K., Krebes K., McNally C., Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J. Bacteriol. 1993, 175:7363-7372.
108. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J. Mol. Microbiol. Biotechnol. 2001, 3:255-264.
109. Price B.M., Galloway D.R., Baker N.R., Gilleland L.B., Staczek J., Gilleland H.E. Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect. Immun. 2001, 69:3510-3515.
110. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 2006, 43(Suppl. 2):S95-S99.
111. Rangel-Vega A., Bernstein L.R., Mandujano-Tinoco E.A., Garcia-Contreras S.J., Garcia-Contreras R. Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Front. Microbiol. 2015, 6:282.
112. Rasmussen T.B., Bjarnsholt T., Skindersoe M.E., Hentzer M., Kristoffersen P., Kote M., Nielsen J., Eberl L., Givskov M. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J. Bacteriol. 2005, 187:1799-1814.
113. Reithofer M.R., Lakshmanan A., Ping A.T., Chin J.M., Hauser C.A. In situ synthesis of size-controlled, stable silver nanoparticles within ultrashort peptide hydrogels and their anti-bacterial properties. Biomaterials 2014, 35:7535-7542.
114. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 2009, 18:237-238. 240-243.
115. Rumbaugh K.P., Griswold J.A., Iglewski B.H., Hamood A.N. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect. Immun. 1999, 67:5854-5862.
116. Sabuda D.M., Laupland K., Pitout J., Dalton B., Rabin H., Louie T., Conly J. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can. J. Infect. Dis. Med. Microbiol. 2008, 19:413-418.
117. Sadikot R.T., Blackwell T.S., Christman J.W., Prince A.S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 2005, 171:1209-1223.
118. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. J. Am. Med. Assoc. 2003, 290:1749-1756.
119. Sajjan U.S., Tran L.T., Sole N., Rovaldi C., Akiyama A., Friden P.M., Forstner J.F., Rothstein D.M. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 2001, 45:3437-3444.
120. Salehi A.H., Montazer M., Toliyat T., Mahmoudi-Rad M. A new route for synthesis of silver:gold alloy nanoparticles loaded within phosphatidylcholine liposome structure as an effective antibacterial agent against Pseudomonas aeruginosa. J. Liposome Res. 2015, 25:38-45.
121. Sato H., Frank D.W. ExoU is a potent intracellular phospholipase. Mol. Microbiol. 2004, 53:1279-1290.
122. Sawa T., Ito E., Nguyen V.H., Haight M. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum. Vaccin. Immunother. 2014, 10:2843-2852.
123. Schaad U.B., Lang A.B., Wedgwood J., Ruedeberg A., Que J.U., Furer E., Cryz S.J. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991, 338:1236-1237.
124. Sharma V.K., Siskova K.M., Zboril R., Gardea-Torresdey J.L. Organic-coated silver nanoparticles in biological and environmental conditions: fate, stability and toxicity. Adv. Colloid Interface Sci. 2014, 204:15-34.
125. Shortridge V.D., Lazdunski A., Vasil M.L. Osmoprotectants and phosphate regulate expression of phospholipase C in Pseudomonas aeruginosa. Mol. Microbiol. 1992, 6:863-871.
126. Smeianov V., Scott K., Reid G. Activity of cecropin P1 and FA-LL-37 against urogenital microflora. Microbes Infect. 2000, 2:773-777.
127. Sobieszczyk M.E., Furuya E.Y., Hay C.M., Pancholi P., Della-Latta P., Hammer S.M., Kubin C.J. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 2004, 54:566-569.
128. Srinivas N., Jetter P., Ueberbacher B.J., Werneburg M., Zerbe K., Steinmann J., Van der Meijden B., Bernardini F., Lederer A., Dias R.L., Misson P.E., Henze H., Zumbrunn J., Gombert F.O., Obrecht D., Hunziker P., Schauer S., Ziegler U., Kach A., Eberl L., Riedel K., DeMarco S.J., Robinson J.A. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 2010, 327:1010-1013.
129. Steinkamp G., Schmitt-Grohe S., Doring G., Staab D., Pfrunder D., Beck G., Schubert R., Zielen S. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir. Med. 2008, 102:1643-1653.
130. Stuart R.K., Pollack M. Pseudomonas aeruginosa exotoxin A inhibits proliferation of human bone marrow progenitor cells in vitro. Infect. Immun. 1982, 38:206-211.
131. Suh S.J., Silo-Suh L., Woods D.E., Hassett D.J., West S.E., Ohman D.E. Effect of rpoS mutation on the stress response and expression of virulence factors in Pseudomonas aeruginosa. J. Bacteriol. 1999, 181:3890-3897.
132. Tambekar D.H., Dahikar S.B. Antibacterial activity of some Indian Ayurvedic preparations against enteric bacterial pathogens. J. Adv. Pharm. Technol. Res. 2011, 2:24-29.
133. Teplitski M., Robinson J.B., Bauer W.D. Plants secrete substances that mimic bacterial N-acyl homoserine lactone signal activities and affect population density-dependent behaviors in associated bacteria. Mol. Plant Microbe Interact. 2000, 13:637-648.
134. Theilacker C., Coleman F.T., Mueschenborn S., Llosa N., Grout M., Pier G.B. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun. 2003, 71:3875-3884.
135. Toder D.S., Ferrell S.J., Nezezon J.L., Rust L., Iglewski B.H. lasA and lasB genes of Pseudomonas aeruginosa: analysis of transcription and gene product activity. Infect. Immun. 1994, 62:1320-1327.
136. Torres-Barcelo C., Arias-Sanchez F.I., Vasse M., Ramsayer J., Kaltz O., Hochberg M.E. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLOS ONE 2014, 9:e106628.
137. Tsuang Y.H., Sun J.S., Huang Y.C., Lu C.H., Chang W.H., Wang C.C. Studies of photokilling of bacteria using titanium dioxide nanoparticles. Artif. Organs 2008, 32:167-174.
138. Valappil S.P., Yiu H.H., Bouffier L., Hope C.K., Evans G., Claridge J.B., Higham S.M., Rosseinsky M.J. Effect of novel antibacterial gallium-carboxymethyl cellulose on Pseudomonas aeruginosa. Dalton Trans. 2013, 42:1778-1786.
139. Valdez J.C., Peral M.C., Rachid M., Santana M., Perdigon G. Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: the potential use of probiotics in wound treatment. Clin. Microbiol. Infect. 2005, 11:472-479.
140. Van Delden C., Iglewski B.H. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg. Infect. Dis. 1998, 4:551-560.
141. van Delden C., Kohler T., Brunner-Ferber F., Francois B., Carlet J., Pechere J.C. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012, 38:1118-1125.
142. Varma P., Nisha N., Dinesh K.R., Kumar A.V., Biswas R. Anti-infective properties of Lactobacillus fermentum against Staphylococcus aureus and Pseudomonas aeruginosa. J. Mol. Microbiol. Biotechnol. 2011, 20:137-143.
143. Veesenmeyer J.L., Hauser A.R., Lisboa T., Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit. Care Med. 2009, 37:1777-1786.
144. Wade D.S., Calfee M.W., Rocha E.R., Ling E.A., Engstrom E., Coleman J.P., Pesci E.C. Regulation of Pseudomonas quinolone signal synthesis in Pseudomonas aeruginosa. J. Bacteriol. 2005, 187:4372-4380.
145. Waters V., Smyth A. Cystic fibrosis microbiology: advances in antimicrobial therapy. J. Cyst. Fibros. 2015, 14:551-560.
146. Willcox M.D., Zhu H., Conibear T.C., Hume E.B., Givskov M., Kjelleberg S., Rice S.A. Role of quorum sensing by Pseudomonas aeruginosa in microbial keratitis and cystic fibrosis. Microbiology 2008, 154:2184-2194.
147. Williamson K.S., Richards L.A., Perez-Osorio A.C., Pitts B., McInnerney K., Stewart P.S., Franklin M.J. Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population. J. Bacteriol. 2012, 194:2062-2073.
148. Wright A., Hawkins C.H., Anggard E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009, 34:349-357.
149. Zhou L., Zheng H., Tang Y., Yu W., Gong Q. Eugenol inhibits quorum sensing at sub-inhibitory concentrations. Biotechnol. Lett. 2013, 35:631-637.